Cumulative impact of procedural and anatomical factors on in-hospital bleeding complications in endovascular therapy for lower-extremity artery disease: A nationwide registry study in Japan.

IF 3 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Vascular Medicine Pub Date : 2025-04-01 Epub Date: 2025-02-24 DOI:10.1177/1358863X251320113
Takuya Nakahashi, Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Kazunori Horie, Kenji Sakata, Masayuki Takamura, Tetsuya Amano, Ken Kozuma
{"title":"Cumulative impact of procedural and anatomical factors on in-hospital bleeding complications in endovascular therapy for lower-extremity artery disease: A nationwide registry study in Japan.","authors":"Takuya Nakahashi, Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Kazunori Horie, Kenji Sakata, Masayuki Takamura, Tetsuya Amano, Ken Kozuma","doi":"10.1177/1358863X251320113","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Although bleeding is a common procedure-related adverse event following endovascular therapy (EVT), limited data exist regarding the procedural and anatomical factors associated with its complications in patients with lower-extremity artery disease (LEAD) undergoing EVT. <b>Methods:</b> Data were extracted from a nationwide Japanese EVT registry of 73,990 patients who underwent EVT for symptomatic LEAD between January 2021 and December 2022. The primary outcome measure was in-hospital bleeding complications, including access site bleeding, nonaccess site bleeding, and hemorrhagic stroke. <b>Results:</b> The mean age of the patients was 75 ± 9 years, and 69% were men. In-hospital bleeding complications were observed in 613 (0.8%) patients. Logistic regression analysis demonstrated significant associations between bleeding complications and the following procedural, anatomical, and pharmacological variables: emergent revascularization (odds ratio [OR]: 1.90, 95% CI: 1.29-2.79), multiple approach sites (OR: 2.46, 95% CI: 2.00-3.01), bilateral arterial calcification (OR: 1.46, 95% CI: 1.19-1.79), chronic occlusion (OR: 1.53, 95% CI: 1.28-1.83), dual antiplatelet therapy (OR: 1.70, 95% CI: 1.27-2.28), and oral anticoagulant (OR: 1.63, 95% CI: 1.31-2.03). The adjusted incidence of in-hospital bleeding was 0.59% (95% CI: 0.51-0.68%) in patients with one of the identified procedural and anatomical risk factors, 0.96% (95% CI: 0.82-1.13%) in patients with two factors, and 2.40% (95% CI: 1.88-3.05%) in patients with three or four factors. <b>Conclusions:</b> Procedural and anatomical factors as well as antithrombotic strategies were significantly associated with an increased risk of in-hospital bleeding in patients with LEAD who underwent EVT.</p>","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":" ","pages":"155-161"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1358863X251320113","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Although bleeding is a common procedure-related adverse event following endovascular therapy (EVT), limited data exist regarding the procedural and anatomical factors associated with its complications in patients with lower-extremity artery disease (LEAD) undergoing EVT. Methods: Data were extracted from a nationwide Japanese EVT registry of 73,990 patients who underwent EVT for symptomatic LEAD between January 2021 and December 2022. The primary outcome measure was in-hospital bleeding complications, including access site bleeding, nonaccess site bleeding, and hemorrhagic stroke. Results: The mean age of the patients was 75 ± 9 years, and 69% were men. In-hospital bleeding complications were observed in 613 (0.8%) patients. Logistic regression analysis demonstrated significant associations between bleeding complications and the following procedural, anatomical, and pharmacological variables: emergent revascularization (odds ratio [OR]: 1.90, 95% CI: 1.29-2.79), multiple approach sites (OR: 2.46, 95% CI: 2.00-3.01), bilateral arterial calcification (OR: 1.46, 95% CI: 1.19-1.79), chronic occlusion (OR: 1.53, 95% CI: 1.28-1.83), dual antiplatelet therapy (OR: 1.70, 95% CI: 1.27-2.28), and oral anticoagulant (OR: 1.63, 95% CI: 1.31-2.03). The adjusted incidence of in-hospital bleeding was 0.59% (95% CI: 0.51-0.68%) in patients with one of the identified procedural and anatomical risk factors, 0.96% (95% CI: 0.82-1.13%) in patients with two factors, and 2.40% (95% CI: 1.88-3.05%) in patients with three or four factors. Conclusions: Procedural and anatomical factors as well as antithrombotic strategies were significantly associated with an increased risk of in-hospital bleeding in patients with LEAD who underwent EVT.

程序和解剖因素对下肢动脉疾病血管内治疗中院内出血并发症的累积影响:日本一项全国性登记研究
背景:尽管出血是血管内治疗(EVT)后常见的手术相关不良事件,但在接受EVT的下肢动脉疾病(LEAD)患者中,手术和解剖因素与并发症相关的数据有限。方法:数据提取自日本全国EVT登记处的73990名患者,这些患者在2021年1月至2022年12月期间因症状性铅接受EVT。主要结局指标为院内出血并发症,包括通路部位出血、非通路部位出血和出血性卒中。结果:患者平均年龄75±9岁,男性占69%。院内出血并发症613例(0.8%)。Logistic回归分析显示,出血并发症与以下手术、解剖和药理学变量之间存在显著相关性:紧急血运重建(优势比[OR]: 1.90, 95% CI: 1.29-2.79)、多个入路部位(OR: 2.46, 95% CI: 2.00-3.01)、双侧动脉钙化(OR: 1.46, 95% CI: 1.19-1.79)、慢性闭塞(OR: 1.53, 95% CI: 1.28-1.83)、双重抗血小板治疗(OR: 1.70, 95% CI: 1.27-2.28)和口服抗凝剂(OR:1.63, 95% ci: 1.31-2.03)。在确定的程序性和解剖学危险因素中,有一种因素的患者调整后的院内出血发生率为0.59% (95% CI: 0.51-0.68%),两种因素的患者调整后的院内出血发生率为0.96% (95% CI: 0.82-1.13%),三种或四种因素的患者调整后的院内出血发生率为2.40% (95% CI: 1.88-3.05%)。结论:手术和解剖因素以及抗血栓策略与行EVT的LEAD患者院内出血风险增加显著相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vascular Medicine
Vascular Medicine 医学-外周血管病
CiteScore
5.70
自引率
5.70%
发文量
158
审稿时长
>12 weeks
期刊介绍: The premier, ISI-ranked journal of vascular medicine. Integrates the latest research in vascular biology with advancements for the practice of vascular medicine and vascular surgery. It features original research and reviews on vascular biology, epidemiology, diagnosis, medical treatment and interventions for vascular disease. A member of the Committee on Publication Ethics (COPE)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信